CCR5 inhibitors in HIV-1 therapy

Expert Opinion on Drug Discovery

Volumn 3, Issue 11, 2008, Pages 1345-1361

  Dorr, Patrick ^a   Perros, Manos ^b  

^a PFIZER INC   (United States)

^b Antirival Research   (United Kingdom)

Author keywords

Antiretroviral; Aplaviroc; ART; CCR5; HAART; HIV 1; INCB9471; Maraviroc; PF 232798; Resistance; SCH 532706; TAK 220; TAK 652; TAK 779; Trofile ; Tropism; Vicriviroc

Indexed keywords

1 ACETYL N [3 [4 (4 CARBAMOYLBENZYL) 1 PIPERIDINYL]PROPYL] N (3 CHLORO 4 METHYLPHENYL) 4 PIPERIDINECARBOXAMIDE; 4 [(4 BROMOPHENYL)(ETHOXYIMINO)METHYL] 1' [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4' METHYL 1,4' BIPIPERIDINE; 4 BENZOYL 1 [(4 METHOXY 1H PYRROLO[2,3 B]PYRIDIN 3 YL)OXOACETYL] 2 METHYLPIPERAZINE; 8 [(4 AMINOBUTYL)(2 BENZIMIDAZOLYLMETHYL)AMINO] 1,2,3,4 TETRAHYDROQUINOLINE; 8 [4 (2 BUTOXYETHOXY)PHENYL] 1,2,3,4 TETRAHYDRO 1 ISOBUTYL N [4 (1 PROPYL 1H IMIDAZOL 5 YLMETHYLSULFINYL)PHENYL] 1 BENZAZOCINE 5 CARBOXAMIDE; ANTIRETROVIRUS AGENT; APLAVIROC; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; GSK 873140; INCB 9471; LAMIVUDINE PLUS ZIDOVUDINE; MARAVIROC; MRK 167; N [3 [4 (3 BENZYL 1 ETHYL 5 PYRAZOLYL) 1 PIPERIDINYLMETHYL] 4 (3 FLUOROPHENYL)CYCLOPENTYL] N METHYLVALINE; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; PF 232798; PLACEBO; PLERIXAFOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SCH 532706; UNCLASSIFIED DRUG; VICRIVIROC;

ABDOMINAL PAIN; ACQUIRED IMMUNE DEFICIENCY SYNDROME; AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SCREENING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLATULENCE; GASTROINTESTINAL SYMPTOM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIVER TOXICITY; LOW DRUG DOSE; LYMPHOMA; MONOTHERAPY; NAUSEA; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; QT PROLONGATION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STOMACH ADENOCARCINOMA; STRUCTURE ACTIVITY RELATION; VIRUS ATTACHMENT; VIRUS ENTRY; VIRUS LOAD; VOMITING;

EID: 56749182203     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.3.11.1345     Document Type: Review

References (147)

1. Masur H, Michelis MA, Greene JB, et al. An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N Engl J Med 1981;305:1431-8
2. Barre-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;220:868-71
3. Gallo RC, Sarin PS, Gelmann EP, et al. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science 1983;220:865-7
4. Available from: http://www.unaids.org/en/KnowledgeCentre/HIVData/ EpiUpdate/EpiUpdArchive/2007/default.asp: 2007 AIDS Pandemic Update. 2008
5. Available from: http://www.aidsmeds.com/list.shtml: Treatments for HIV and AIDS. 2008
6. Vercauteren J, Deforche K, Theys K, et al. The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in Portugal. Retrovirology 2008;5:12
7. Carr A. Toxicity of antiretroviral therapy and implications for drug development. Nat Rev Drug Discov 2003;2:624-34
8. Lunzen J. Treatment of heavily antiretroviral-experienced HIV-infected patients. AIDS Rev 2007;9:246-53
9. Richman DD, Morton SC, Wrin T, et al. The prevalence of antiretroviral drug resistance in the United States. Aids 2004;18:1393-401
10. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002;347:385-94
11. Shet A, Berry L, Mohri H, et al. Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience. J Acquir Immune Defic Syndr 2006;41:439-46
12. Cabrera C. Raltegravir, an HIV-1 integrase inhibitor for HIV infection. Curr Opin Investig Drugs 2008;9:885-98
13. Summa V, Petrocchi A, Bonelli F, et al. Discovery of Raltegravir, a Potent, Selective Orally Bioavailable HIV-Integrase Inhibitor for the Treatment of HIV-AIDS Infection. J Med Chem 2008;3:3
14. Charpentier C, Karmochkine M, Laureillard D, et al. Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy. HIV Med 2008;21:21
15. Derdeyn CA, Decker JM, Sfakianos JN, et al. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor. J Virol 2001;75:8605-14
16. Pierson TC, Doms RW, Pohlmann S. Prospects of HIV-1 entry inhibitors as novel therapeutics. Rev Med Virol 2004;14:255-70
17. Moore JP, Doms RW. The entry of entry inhibitors: a fusion of science and medicine. Proc Natl Acad Sci USA 2003;100:10598-602. [Epub 12003 Sep 10595.]
18. Chen RY, Kilby JM, Saag MS. Enfuvirtide. [Review] [27 refs]. Expert Opin Investig Drugs 2002;11:1837-43
19. Greenberg ML, Cammack N. Resistance to enfuvirtide, the first HIV fusion inhibitor. J Antimicrob Chemother 2004;54:333-40
20. Lin PF, Blair W, Wang T, et al. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. [see comment]. Proc Natl Acad Sci USA 2003;100:11013-8
21. Hendrix CW, Collier AC, Lederman MM, et al. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr 2004;37:1253-62
22. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006;354:610-21
23. Wise A, Gearing K, Rees S. Target validation of G-protein coupled receptors. Drug Discov Today 2002;7:235-46
24. Choe H, Farzan M, Sun Y, et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996;85:1135-48
25. Deng H, Liu R, Ellmeier W, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996;381:661-6
26. Dragic T, Litwin V, Allaway GP, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996;381:667-73
27. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996;272:872-7
28. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996;273:1856-62
29. Huang Y, Paxton WA, Wolinsky SM, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996;2:1240-3
30. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996;86:367-77
31. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. [see comment]. Nature 1996;382:722-5
32. Ometto L, Bertorelle R, Mainardi M, et al. Polymorphisms in the CCR5 promoter region influence disease progression in perinatally human immunodeficiency virus type 1-infected children. J Infect Dis 2001;183:814-8. [Epub 2001 Jan 2024]
33. Schuitemaker H, Kootstra NA, De Goede RE, et al. Monocytotropic human immunodeficiency virus type 1 (HIV-1) variants detectable in all stages of HIV-1 infection lack T-cell line tropism and syncytium-inducing ability in primary T-cell culture. J Virol 1991;65:356-63
34. Shankarappa R, Margolick JB, Gange SJ, et al. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 1999;73:10489-502
35. Zhu T, Mo H, Wang N, et al. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 1993;261:1179-81
36. Karlsson I, Antonsson L, Shi Y, et al. HIV biological variability unveiled: frequent isolations and chimeric receptors reveal unprecedented variation of coreceptor use. Aids 2003;17:2561-9
37. Koning FA, Kwa D, Boeser-Nunnink B, et al. Decreasing sensitivity to RANTES (regulated on activation, normally T cell-expressed and -secreted) neutralization of CC chemokine receptor 5-using, non-syncytium-inducing virus variants in the course of human immunodeficiency virus type 1 infection. J Infect Dis 2003;188:864-72
38. Sullivan WM, Dorr P, Perros M, et al. Lack of alternative coreceptor use by pediatric HIV-1 R5 isolates for infection of primary cord or adult peripheral blood mononuclear cells. Arch Virol 2008;153:363-6. [Epub 2007 Dec 2013.]
39. Fatkenheuer G, Pozniak AL, Johnson MA, et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 2005;11:1170-2
40. Lalezari J, Goodrich J, DeJesus E, et al. Efficacy and Safety of Maraviroc plus Optimized Background Therapy in Viremic ART-experienced Patients Infected with CCR5-tropic HIV-1: 24-Week Results of a Phase 2b/ 3 Study in the US and Canada [abstract. 104bLB]. 14th Conference on Retroviruses and Opportunistic Infections 2007
41. Lalezari J, Thompson M, Kumar P, et al. Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults. Aids 2005;19:1443-8
42. Nelson M, Fätkenheuer G, Konourina I, et al. Efficacy and Safety of Maraviroc plus Optimized Background Therapy in Viremic, ART-experienced Patients Infected with CCR5-tropic HIV-1 in Europe, Australia, and North America: 24-Week Results 14th Conference on Retroviruses and Opportunistic Infections [abstract 104aLB]. Los Angeles: 2007
43. Thelen M. Dancing to the tune of chemokines. Nat Immunol 2001;2:129-34
44. Mueller A, Strange PG. The chemokine receptor, CCR5. Int J Biochem Cell Biol 2004;36:35-8
45. Cocchi F, DeVico AL, Garzino-Demo A, et al. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995;270:1811-5
46. Eri R, Jonsson JR, Pandeya N, et al. CCR5-Delta32 mutation is strongly associated with primary sclerosing cholangitis. Genes Immun 2004;5:444-50
47. Henckaerts L, Fevery J, Van Steenbergen W, et al. CC-type chemokine receptor 5-Delta32 mutation protects against primary sclerosing cholangitis. Inflamm Bowel Dis 2006;12:272-7
48. Pokorny V, McQueen F, Yeoman S, et al. Evidence for negative association of the chemokine receptor CCR5 d32 polymorphism with rheumatoid arthritis. Ann Rheum Dis 2005;64:487-90
49. Prahalad S. Negative association between the chemokine receptor CCR5-Delta32 polymorphism and rheumatoid arthritis: a meta-analysis. Genes Immun 2006;7:264-8
50. Bursill CA, Channon KM, Greaves DR. The role of chemokines in atherosclerosis: recent evidence from experimental models and population genetics. Curt Opin Lipidol 2004;15:145-9
51. Van Wanrooij EJ, Happe H, Hauer AD, et al. HIV entry inhibitor TAK-779 attenuates atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2005;25:2642-7
52. Zernecke A, Shagdarsuren E, Weber C. Chemokines in Atherosclerosis. An Update. Arterioscler Thromb Vasc Biol 2008;19:19
53. Bracke KR, D'Hulst AI, Maes T, et al. Cigarette smoke-induced pulmonary inflammation, but not airway remodelling, is attenuated in chemokine receptor 5-deficient mice. Clin Exp Allergy 2007;37:1467-79
54. Goulding C, McManus R, Murphy A, et al. The CCR5-delta32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source. Gut 2005;54:1157-61
55. Wald O, Pappo O, Ari ZB, et al. The CCR5Delta32 allele is associated with reduced liver inflammation in hepatitis C virus infection. Eur J Immun 2004;31:249-52
56. Zeremski M, Petrovic LM, Talal AH. The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection. J Viral Hepat 2007;14:675-87
57. Schwabe RF, Bataller R, Brenner DA. Human hepatic stellate cells express CCR5 and RANTES to induce proliferation and migration. Am J Physiol Gastrointest Liver Physiol 2003;285:G949-58. [Epub 2003 Jun 2026]
58. Diamond MS, Klein RS. A genetic basis for human susceptibility to West Nile virus. Trends Microbiol 2006;14:287-9. [Epub 2006 Jun 2005]
59. Lim JK, Glass WG, McDermott DH, Murphy PM. CCR5: no longer a "good for nothing" gene-chemokine control of West Nile virus infection. Trends Immunol 2006;27:308-12. [Epub 2006 Jun 2005]
60. Lim JK, Louie CY, Glaser C, et al. Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic. J Infect Dis 2008;197:262-5
61. Westby M, Van Der Ryst E. CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection. Antivir Chem Chemother 2005;16:339-54
62. Emmelkamp JM, Rockstroh JK. CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions-review of the literature. Eur J Med Res 2007;12:409-17
63. Mosier DE, Picchio GR, Gulizia RJ, et al. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants. J Virol 1999;73:3544-50
64. Gaertner H, Lebeau O, Borlat I, et al. Highly potent HIV inhibition: engineering a key anti-HIV structure from PSC-RANTES into MIP-1 beta/ CCL4. Protein Eng Des Sel 2008;21:65-72. [Epub 2008 Jan 2004]
65. Lalezari J, Yadavalli GK, Para M, et al. Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients. J Infect Dis 2008;197:721-7
66. Poli G. PRO-140 (Progenics). IDrugs 2001;4:1068-71
67. Combadiere C, Ahuja SK, Tiffany HL, Murphy PM. Cloning and functional expression of CC CKR5, a human monocyte CC chemokine receptor selective for MIP-1(alpha), MIP-1(beta), and RANTES. J Leukoc Biol 1996;60:147-52
68. Armour DR, De Groot MJ, Price DA, et al. The Discovery of Tropane-derived CCR5 Receptor Antagonists. Chem Biol Drug Des 2006;67:305-8
69. Baba M, Nishimura O, Kanzaki N, et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 1999;96:5698-03
70. Castonguay LA, Weng Y, Adolfsen W, et al. Binding of 2-aryl-4-(piperidin-1-yl) butanamines and 1,3,4-trisubstituted pyrrolidines to human CCR5: a molecular modeling-guided mutagenesis study of the binding pocket. Biochemistry 2003;42:1544-50
71. Dory P, Westby M, Dobbs S, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005;49:4721-32
72. Maeda K, Yoshimura K, Shibayama S, et al. Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5. J Biol Chem 2001;276:35194-200
73. Shiraishi M, Aramaki Y, Seto M, et al. Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety. J Med Chem 2000;43:2049-63
74. Strizki JM, Xu S, Wagner NE, et al. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo Proc Natl Acad Sci USA 2001;98:12718-23
75. Maeda K, Nakata H, Koh Y, et al. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro J Virol 2004;78:8654-62
76. Watson C, Jenkinson S, Kazmierski W, Kenakin T: The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol Pharmacol 2005;67:1268-82
77. Nichols WG, Steel HM, Bonny T, et al. Hepatotoxicity observed in clinical trials of aplaviroc (GW873140). Antimicrob Agents Chemother 2008;52:858-65. [Epub 2007 Dec 2010]
78. Cohen C DE, Mills A, Pierone G Jr, et al. Potent antiretroviral activity of the once-daily CCR5 antagonist INCB009471 over 14 days of monotherapy 4th international AIDS Society Conference 2007
79. Erickson-Viitanen S AK, Solomon K, Levy R, et al. Co-receptor Tropism, ENV Genotype, and in vitro Susceptibility to CCR5 Antagonists during a 14-Day Monotherapy Study with INCB9471 [abstract 862]. 15. th Conference on Retroviruses and Opportunistic Infections. 2008.
80. Available from: http://www.incyte.com/drugs_product_pipeline.html: Incyte Drug Pipeline. 2008
81. Abel S, Van Der Ryst E, Muihead GJ, et al. Pharmacokinetics of Single and Multiple Oral Doses of UK-427,857-A Novel CCR5 Antagonist in Healthy Volunteers [abstract 547]. In 10th Conference on Retroviruses and Opportunistic Infections. Edited by. Boston; 2003
82. Walker DK, Abel S, Comby P, et al. Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Drug Metab Dispos 2005;33:587-95
83. Russell D, Bakhtyari A, Jazrawi RP, et al. Multiple dose study to investigate the safety of UK-427,857 (100 mg or 300mg) BID for 28 days in healthy males and females. In 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Edited by. Chicago, IL, USA; 2003
84. Ayoub A, Van Der Ryst E, Turner K, McHale M: A Review of the Markers of Immune Function during the Maraviroc Phase I and Ila Studies [abstract 509]. 14th Conference on Retroviruses and Opportunistic Infections 2007
85. Hoepelman I, Ayoub A, Heera J. The Incidence of Severe Liver Enzyme Abnormalities and Hepatic Adverse Events in the Maraviroc Clinical Development Programme. 11th European AIDS Conference (EACS). 2007
86. Mayer H, Van Der Ryst E, Saag M, et al. Safety and Efficacy of Maraviroc (MVC), a Novel CCR5 Antagonist, When Used in Combination with Optimized Background Therapy (OBT) for the Treatment of Antiretroviral-Experienced Subjects Infected with Dual/Mixed-Tropic HIV-1: 24-Week Results of a Phase 2b Exploratory Trial [abstract THLB0215]. 16th International AIDS Conference 2006
87. Lusso P. HIV and the chemokine system: 10 years later. Embo J 2006;25:447-56. [Epub 2006 Jan 2026]
88. Demarest J BT, Vavro C, Labranche C, et al. HIV-1 co-receptor tropism in treatment naive and experienced subjects [abstract H-1136]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2004
89. Hoffmann C. The epidemiology of HIV coreceptor tropism. Eur J Med Res 2007;12:385-90
90. Saag M, Ive P, Heera J, et al. A Multicenter, Randomized, Double-Blind, Comparative Trial of a Novel CCR5 Antagonist, Maraviroc Versus Efavirenz, both in Combination with Combivir (Zidovudine/Lamivudine), for the Treatment of Antiretroviral-Naive Subjects Infected with R5 HIV 1: Week 48 Results of the MERIT Study [abstrac tWESS104]. 4th International AIDS Symposium; 2007
91. Bredeek UF, Harbour MJ. CCR5 antagonists in the treatment of treatment-naive patients infected with CCR5 tropic HIV-1. Eur J Med Res 2007;12:427-34
92. Dorr P, Westby M, McFadyen L, et al. PF-232798, a Second Generation Oral CCR5 Antagonist [abstract 737]. 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February, 2008. Boston; 2008
93. Dorr P, Todd K, Irvine B, et al. Site-Directed Mutagenesis Studies of CCR5 Reveal Differences in the Interactions between the Receptor and Various CCR5 Antagonists. In 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Edited by. Washington DC, USA; 2005
94. Westby M, Smith-Burchnell C, Hamilton D, et al. UK-427,857-resistant Primary Isolates are Susceptible to Structurally-related CCR5 Antagonists. In 12th Conference on Retroviruses and Opportunistic Infections. Edited by. Boston, MA; 2005
95. Van Der Ryst E, Wood A, Dorr P, et al. Challenges in the Design and Development of Maraviroc, a Novel CCR5 Antagonist for the Treatment of CCR5-tropic HIV-1 Infection. Chemokines and Chemokine Receptors Symposium; 2008
96. Kondru R, Zhang J, Ji C, et al. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Mol Pharmacol 2008;73:789-800. [Epub 2007 Dec 2020]
97. Dorn CP, Finke PE, Oates B, et al. Antagonists of the human CCR5 receptor as anti-HIV-1 agents. part 1: discovery and initial structure-activity relationships for 1-amino-2-phenyl-4-(piperidin-1-yl) butanes. Bioorg Med Chem Lett 2001;11:259-64
98. Shen DM, Shu M, Mills SG, et al. Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 1: Discovery and SAR study of 4-pyrazolylpiperidine side chains. Bioorg Med Chem Lett 2004;14:935-9
99. Shen DM, Shu M, Willoughby CA, et al. Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 2: Discovery of potent, selective, and orally bioavailable compounds. Bioorg Med Chem Lett 2004;14:941-5
100. Shu M, Loebach JL, Parker KA, et al. Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 3: SAR studies on the benzylpyrazole segment. Bioorg Med Chem Lett 2004;14:947-52
101. Veazey RS, Masse PJ, Ketas TJ, et al. Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection. J Exp Med 2003;198:1551-62
102. Veazey RS, Klasse PJ, Schader SM, et al. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 2005;438:99-102
103. Veazey RS, Springer MS, Marx PA, et al. Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor. Nat Med 2005;11:1293-4. [Epub 2005 Nov 1296]
104. MERCK & CO. I: WO/2003/061659; 2003
105. Schroder C, Pierson RN 3rd, Nguyen BN, et al. CCR5 blockade modulates inflammation and alloimmunity in primates. J Immunol 2007;179:2289-99
106. Este JA. Sch-351125 and Sch-350634. Schering-Plough. Curr Opin Investig Drugs 2002;3:379-83
107. Strizki JM, Tremblay C, Xu S, et al. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother 2005;49:4911-9
108. Zingman B, Suleiman J, DeJesus E, et al. Vicriviroc, a Next Generation CCR5 Antagonist, Exhibits Potent, Sustained Suppression of Viral Replication in Treatment-experienced Adults: VICTOR-E1 48-week Results [abstract 39LB]. 15th Conference on Retroviruses and Opportunistic Infections. 2008
109. Greaves W, Landovitz R, Fatkenheuer G, et al. Late Virologic Breakthrough in Treatment-naive Patients on a Regimen of Combivir + Vicriviroc. In 13th Conference on Retroviruses and Opportunistic Infections. Edited by. Denver, CO; 2006
110. Available from: http://www.schering-plough.com/schering_plough/: Schering-Plough News Release. 2008
111. Pett S, Emery S, MacRae K, et al. Safety and Activity of SCH532706, a Small Molecule Chemokine Receptor 5 Antagonist in HIV-1-infected Individuals [abstract 38]. 15th Conference on Retroviruses and Opportunistic Infections. 2008
112. Imamura S, Ichikawa T, Nishikawa Y, et al. Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent Anti-HIV-1 activity. J Med Chem 2006;49:2784-93
113. Takashima K, Miyake H, Kanzaki N, et al. Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist. Antimicrob Agents Chemother 2005;49:3474-82
114. Tremblay CL, Giguel F, Guan Y, et al. TAK-220, a novel small-molecule CCR5 antagonist, has favorable anti-human immunodeficiency virus interactions with other antiretrovirals in vitro Antimicrob Agents Chemother 2005;49:3483-5
115. Baba M, Takashima K, Miyake H, et al. TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans. Antimicrob Agents Chemother 2005;49:4584-91
116. Tremblay CL, Giguel F, Chou TC, et al. TAK-652, a novel CCR5 inhibitor, has favourable drug interactions with other antiretrovirals in vitro Antivir Ther 2005;10:967-8
117. Westby M, Smith-Burchnell C, Mori J, et al. In vitro Escape of R5 Primary Isolates from the CCR5 Antagonist, UK-427,857, is Difficult to Achieve and Involves Continued Use of the CCR5 Receptor. In XIII International HIV Drug Resistance Workshop. Edited by. Tenerife; 2004
118. Stoddart SX C, Wojcik J, Riley J, Strizki J. Evaluation of In Vivo HIV-1 Escape from SCH-C (SCH 351125) [abstract 614]. 13th conference on Retroviruses and Opportunistic Infections 2003
119. Trkola A, Kuhmann SE, Strizki JM, et al. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci USA 2002;99:395-400
120. Liu S, Fan S, Sun Z. Structural and functional characterization of the human CCR5 receptor in complex with HIV gp120 envelope glycoprotein and CD4 receptor by molecular modeling studies. J Mol Model 2003;9:329-36. [Epub 2003 Aug 2029]
121. Navenot JM, Wang ZX, Trent JO, et al. Molecular anatomy of CCR5 engagement by physiologic and viral chemokines and HIV-1 envelope glycoproteins: differences in primary structural requirements for RANTES, MIP-1 alpha, and vMIP-II Binding. J Mol Biol 2001;313:1181-93
122. Zhou N, Luo Z, Hall JW, et al. Molecular modeling and site-directed mutagenesis of CCR5 reveal residues critical for chemokine binding and signal transduction. Eur J Immunol 2000;30:164-73
123. Blanpain C, Doranz BJ, Bondue A, et al. The core domain of chemokines binds CCR5 extracellular domains while their amino terminus interacts with the transmembrane helix bundle. J Biol Chem 2003;278:5179-87. [Epub 2002 Dec 5173]
124. Heera J, Saag M, Ive P, et al. Virological Correlates Associated with Treatment Failure at Week 48 in the Phase 3 Study of Maraviroc in Treatment-naive Patients [abstract 40LB]. 15th Conference on Retroviruses and Opportunistic Infections 2008
125. Lewis M, Simpson P, Fransen S, Westby M: CXCR4-using virus detected in patients receiving maraviroc in the Phase III studies MOTIVATE 1 and 2 originates from a pre-existing minority of CXCR4-using virus [abstract 56]. XVI International HIV Drug Resistance Workshop 2007
126. Lewis M, Mori J, Simpson P, et al. Changes in V3 Loop Sequence Associated with Failure of Maraviroc Treatment in Patients Enrolled in the MOTIVATE 1 and 2 Trials [abstract 871]. 15th Conference on Retroviruses and Opportunistic Infections 2008
127. Marozsan AJ, Kuhmann SE, Morgan T, et al. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology 2005;338:182-99
128. Pugach P, Marozsan AJ, Ketas TJ, et al. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology 2007;361:212-28
129. Westby M, Smith-Burchnell C, Mori J, et al. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 2007;81:2359-71
130. Tsibris AM, Sagar M, Gulick RM, et al. In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J Virol 2008;82:8210-4. [Epub 2008 May 8221]
131. Kuhmann SE, Hartley O. Targeting chemokine receptors in HIV: a status report. Annu Rev Pharmacol Toxicol 2008;48:425-61
132. Kuhmann SE, Pugach P, Kunstman KJ, et al. Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J Virol 2004;78:2790-807
133. Ogert RA, Wojcik L, Buontempo C, et al. Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120. Virology 2008;373:387-99
134. Westby M, Mori J, Smith-Burchnell C, et al. Maraviroc (UK-427,857)-resistant HIV-1 variants Are Sensitive to CCR5 Antagonists and Enfuvirtide. XIV International HIV Drug Resistance Workshop 2005
135. Ogert R, Buontempo O, Wojcik L, et al. Mapping of Vicriviroc Resistance Mutations in HIV-1 gp120 Generated by in vitro Selection of a Primary HIV-1 Isolate in PM-1 Cells 16th Intl HIV Drug Resistance Workshop 2007
136. Rosario MC, Jacqmin P, Dorr P et al. Population pharmacokinetic/ pharmacodynamic analysis of CCR5 receptor occupancy by maraviroc in healthy subjects and HIV-positive patients. Br J Clin Pharmacol 2008;65:86-94
137. Rosario MC, Jacqmin P, Dorr P, et al. A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc. Clin Pharmacol Ther 2005;78:508-19. [Epub 2005 Sep 2028]
138. Comte L, Vrijens B, Tousset E, et al. Estimation of the comparative therapeutic superiority of QD and BID dosing regimens, based on integrated analysis of dosing history data and pharmacokinetics. J Pharmacokinet Pharmacodyn 2007;34:549-58. [Epub 2007 May 2012]
139. Trinh L, Han D, Huang W, et al. Technical Validation of an Enhanced Sensitivity Trofile HIV Co-receptor Tropism Assay for Selecting Patients for Therapy with Entry Inhibitors Targeting CCR5. XVII International HIV Drug Resistance Workshop Sitges, Spain 2008
140. Sen S, Tripathy SP, Paranjape RS. Antiretroviral drug resistance testing. J Postgrad Med 2006;52:187-93
141. Burger H, Weiser B, Anastos K, et al. Preferential Suppression of CXCR4 Specific HIV-1 Strains by Antiviral Therapy and Dynamics of Response [abstract no. I-13221. Interscience Conference Antimicrobial Agents Chemotherapy 2003
142. Soulie C, Marcelin AG, Ghosn J, et al. HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART. Aids 2007;21:2243-5
143. Buchbinder S. HIV Testing and Prevention Strategies. Top HIV Med 2008;16:9-14
144. Available from: http://www.ipm-microbicides.org/: International Partnership for Microbicides. 2008
145. Dumond J, Patterson K, Pecha A, et al. Maraviroc (MVC) Pharmacokinetics (PK) in Blood Plasma (BP), Genital Tract (GT) Fluid and Tissue in Healthy Female Volunteers [abstract 135LB]. 15th Conference on Retroviruses and Opportunistic Infections. 2008
146. Lederman MM, Veazey RS, Offord R, et al. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 2004;306:485-7
147. Dumond JB, Yeh RF, Patterson KB, et al. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. Aids 2007;21:1899-907